Market Research Logo

Generics Global Group of Eight (G8) Industry Guide_2017

Generics Global Group of Eight (G8) Industry Guide_2017

Summary

The G8 Generics industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the G8 generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies.

  • The G8 countries contributed $189.4 billion in 2016 to the global generics industry, with a compound annual growth rate (CAGR) of 10.9% between 2012 and 2016. The G8 countries are expected to reach a value of $384.0 billion in 2021, with a CAGR of 15.2% over the 2016-21 period.
  • Among the G8 nations, the US is the leading country in the generics industry, with market revenues of $99.7 billion in 2016. This was followed by Japan and Germany, with a value of $56.6 and $8.5 billion, respectively.
  • Japan is expected to lead the generics industry in the G8 nations with a value of $199.9 billion in 2016, followed by the US and the UK with expected values of $141.2 and $12.1 billion, respectively.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the G8 generics market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 generics market
  • Leading company profiles reveal details of key generics market players’ G8 operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the G8 generics market with five year forecasts by both value and volume
  • Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country
Reasons to buy
  • What was the size of the G8 generics market by value in 2016?
  • What will be the size of the G8 generics market in 2021?
  • What factors are affecting the strength of competition in the G8 generics market?
  • How has the market performed over the last five years?
  • Who are the top competitors in the G8 generics market?


Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
Group of Eight (G) Generics
Industry Outlook
Generics in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in France
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Germany
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Italy
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Japan
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Russia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United Kingdom
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine
List of Tables
Table 1: G8 generics industry, revenue($bn), 2012-21
Table 2: G8 generics industry, revenue by country ($bn), 2012-16
Table 3: G8 generics industry forecast, revenue by country ($bn), 2016-21
Table 4: Canada generics market value: $ billion, 2012–16
Table 5: Canada generics market volume: % of total pharma volume, 2012–16
Table 6: Canada generics market geography segmentation: $ billion, 2016
Table 7: Canada generics market value forecast: $ billion, 2016–21
Table 8: Canada generics market volume forecast: % of total pharma volume, 2016–21
Table 9: Canada size of population (million), 2012–16
Table 10: Canada gdp (constant 2005 prices, $ billion), 2012–16
Table 11: Canada gdp (current prices, $ billion), 2012–16
Table 12: Canada inflation, 2012–16
Table 13: Canada consumer price index (absolute), 2012–16
Table 14: Canada exchange rate, 2012–16
Table 15: France generics market value: $ billion, 2012–16
Table 16: France generics market volume: % of total pharma volume, 2012–16
Table 17: France generics market geography segmentation: $ billion, 2016
Table 18: France generics market value forecast: $ billion, 2016–21
Table 19: France generics market volume forecast: % of total pharma volume, 2016–21
Table 20: France size of population (million), 2012–16
Table 21: France gdp (constant 2005 prices, $ billion), 2012–16
Table 22: France gdp (current prices, $ billion), 2012–16
Table 23: France inflation, 2012–16
Table 24: France consumer price index (absolute), 2012–16
Table 25: France exchange rate, 2012–16
Table 26: Germany generics market value: $ billion, 2012–16
Table 27: Germany generics market volume: % of total pharma volume, 2012–16
Table 28: Germany generics market geography segmentation: $ billion, 2016
Table 29: Germany generics market value forecast: $ billion, 2016–21
Table 30: Germany generics market volume forecast: % of total pharma volume, 2016–21
Table 31: Germany size of population (million), 2012–16
Table 32: Germany gdp (constant 2005 prices, $ billion), 2012–16
Table 33: Germany gdp (current prices, $ billion), 2012–16
Table 34: Germany inflation, 2012–16
Table 35: Germany consumer price index (absolute), 2012–16
Table 36: Germany exchange rate, 2012–16
Table 37: Italy generics market value: $ billion, 2012–16
Table 38: Italy generics market volume: % of total pharma volume, 2012–16
Table 39: Italy generics market geography segmentation: $ billion, 2016
Table 40: Italy generics market value forecast: $ billion, 2016–21
Table 41: Italy generics market volume forecast: % of total pharma volume, 2016–21
Table 42: Italy size of population (million), 2012–16
Table 43: Italy gdp (constant 2005 prices, $ billion), 2012–16
Table 44: Italy gdp (current prices, $ billion), 2012–16
Table 45: Italy inflation, 2012–16
Table 46: Italy consumer price index (absolute), 2012–16
Table 47: Italy exchange rate, 2012–16
Table 48: Japan generics market value: $ billion, 2012–16
Table 49: Japan generics market volume: % of total pharma volume, 2012–16
Table 50: Japan generics market geography segmentation: $ billion, 2016
Table 51: Japan generics market value forecast: $ billion, 2016–21
Table 52: Japan generics market volume forecast: % of total pharma volume, 2016–21
Table 53: Japan size of population (million), 2012–16
Table 54: Japan gdp (constant 2005 prices, $ billion), 2012–16
Table 55: Japan gdp (current prices, $ billion), 2012–16
Table 56: Japan inflation, 2012–16
Table 57: Japan consumer price index (absolute), 2012–16
Table 58: Japan exchange rate, 2012–16
Table 59: Russia generics market value: $ billion, 2012–16
Table 60: Russia generics market volume: % of total pharma volume, 2012–16
Table 61: Russia generics market geography segmentation: $ billion, 2016
Table 62: Russia generics market value forecast: $ billion, 2016–21
Table 63: Russia generics market volume forecast: % of total pharma volume, 2016–21
Table 64: Russia size of population (million), 2012–16
Table 65: Russia gdp (constant 2005 prices, $ billion), 2012–16
Table 66: Russia gdp (current prices, $ billion), 2012–16
Table 67: Russia inflation, 2012–16
Table 68: Russia consumer price index (absolute), 2012–16
Table 69: Russia exchange rate, 2012–16
Table 70: United Kingdom generics market value: $ billion, 2012–16
Table 71: United Kingdom generics market volume: % of total pharma volume, 2012–16
Table 72: United Kingdom generics market geography segmentation: $ billion, 2016
Table 73: United Kingdom generics market value forecast: $ billion, 2016–21
Table 74: United Kingdom generics market volume forecast: % of total pharma volume, 2016–21
Table 75: United Kingdom size of population (million), 2012–16
Table 76: United Kingdom gdp (constant 2005 prices, $ billion), 2012–16
Table 77: United Kingdom gdp (current prices, $ billion), 2012–16
Table 78: United Kingdom inflation, 2012–16
Table 79: United Kingdom consumer price index (absolute), 2012–16
Table 80: United Kingdom exchange rate, 2012–16
Table 81: United States generics market value: $ billion, 2012–16
Table 82: United States generics market volume: % of total pharma volume, 2012–16
Table 83: United States generics market geography segmentation: $ billion, 2016
Table 84: United States generics market value forecast: $ billion, 2016–21
Table 85: United States generics market volume forecast: % of total pharma volume, 2016–21
Table 86: United States size of population (million), 2012–16
Table 87: United States gdp (constant 2005 prices, $ billion), 2012–16
Table 88: United States gdp (current prices, $ billion), 2012–16
Table 89: United States inflation, 2012–16
Table 90: United States consumer price index (absolute), 2012–16
Table 91: United States exchange rate, 2012–15
Table 92: Apotex, Inc.: key facts
Table 93: Mylan Inc.: key facts
Table 94: Mylan Inc.: key financials ($)
Table 95: Mylan Inc.: key financial ratios
Table 96: Sandoz International GmbH: key facts
Table 97: Teva Pharmaceutical Industries Limited: key facts
Table 98: Teva Pharmaceutical Industries Limited: key financials ($)
Table 99: Teva Pharmaceutical Industries Limited: key financial ratios
Table 100: Les Laboratoires Servier: key facts
Table 101: STADA Arzneimittel AG: key facts
Table 102: STADA Arzneimittel AG: key financials ($)
Table 103: STADA Arzneimittel AG: key financials (€)
Table 104: STADA Arzneimittel AG: key financial ratios
Table 105: Sanofi SA: key facts
Table 106: Sanofi SA: key financials ($)
Table 107: Sanofi SA: key financials (€)
Table 108: Sanofi SA: key financial ratios
Table 109: Daiichi Sankyo Co., Ltd.: key facts
Table 110: Daiichi Sankyo Co., Ltd.: key financials ($)
Table 111: Daiichi Sankyo Co., Ltd.: key financials (¥)
Table 112: Daiichi Sankyo Co., Ltd.: key financial ratios
Table 113: Sawai Pharmaceutical Co., Ltd.: key facts
Table 114: Sawai Pharmaceutical Co., Ltd.: key financials ($)
Table 115: Sawai Pharmaceutical Co., Ltd.: key financials (¥)
Table 116: Sawai Pharmaceutical Co., Ltd.: key financial ratios
Table 117: Abbott Laboratories: key facts
Table 118: Abbott Laboratories: key financials ($)
Table 119: Abbott Laboratories: key financial ratios
Table 120: Krka, d. d., Novo mesto: key facts
Table 121: Krka, d. d., Novo mesto: key financials ($)
Table 122: Krka, d. d., Novo mesto: key financials (€)
Table 123: Krka, d. d., Novo mesto: key financial ratios
List of Figures
Figure 1: G8 generics industry, revenue($bn), 2012-21
Figure 2: G8 Generics industry, revenue by country (%), 2016
Figure 3: G8 generics industry, revenue by country ($bn), 2012-16
Figure 4: G8 generics industry forecast, revenue by country ($bn), 2016-21
Figure 5: Canada generics market value: $ billion, 2012–16
Figure 6: Canada generics market volume: % of total pharma volume, 2012–16
Figure 7: Canada generics market geography segmentation: % share, by value, 2016
Figure 8: Canada generics market value forecast: $ billion, 2016–21
Figure 9: Canada generics market volume forecast: % of total pharma volume, 2016–21
Figure 10: Forces driving competition in the generics market in Canada, 2016
Figure 11: Drivers of buyer power in the generics market in Canada, 2016
Figure 12: Drivers of supplier power in the generics market in Canada, 2016
Figure 13: Factors influencing the likelihood of new entrants in the generics market in Canada, 2016
Figure 14: Factors influencing the threat of substitutes in the generics market in Canada, 2016
Figure 15: Drivers of degree of rivalry in the generics market in Canada, 2016
Figure 16: France generics market value: $ billion, 2012–16
Figure 17: France generics market volume: % of total pharma volume, 2012–16
Figure 18: France generics market geography segmentation: % share, by value, 2016
Figure 19: France generics market value forecast: $ billion, 2016–21
Figure 20: France generics market volume forecast: % of total pharma volume, 2016–21
Figure 21: Forces driving competition in the generics market in France, 2016
Figure 22: Drivers of buyer power in the generics market in France, 2016
Figure 23: Drivers of supplier power in the generics market in France, 2016
Figure 24: Factors influencing the likelihood of new entrants in the generics market in France, 2016
Figure 25: Factors influencing the threat of substitutes in the generics market in France, 2016
Figure 26: Drivers of degree of rivalry in the generics market in France, 2016
Figure 27: Germany generics market value: $ billion, 2012–16
Figure 28: Germany generics market volume: % of total pharma volume, 2012–16
Figure 29: Germany generics market geography segmentation: % share, by value, 2016
Figure 30: Germany generics market value forecast: $ billion, 2016–21
Figure 31: Germany generics market volume forecast: % of total pharma volume, 2016–21
Figure 32: Forces driving competition in the generics market in Germany, 2016
Figure 33: Drivers of buyer power in the generics market in Germany, 2016
Figure 34: Drivers of supplier power in the generics market in Germany, 2016
Figure 35: Factors influencing the likelihood of new entrants in the generics market in Germany, 2016
Figure 36: Factors influencing the threat of substitutes in the generics market in Germany, 2016
Figure 37: Drivers of degree of rivalry in the generics market in Germany, 2016
Figure 38: Italy generics market value: $ billion, 2012–16
Figure 39: Italy generics market volume: % of total pharma volume, 2012–16
Figure 40: Italy generics market geography segmentation: % share, by value, 2016
Figure 41: Italy generics market value forecast: $ billion, 2016–21
Figure 42: Italy generics market volume forecast: % of total pharma volume, 2016–21
Figure 43: Forces driving competition in the generics market in Italy, 2016
Figure 44: Drivers of buyer power in the generics market in Italy, 2016
Figure 45: Drivers of supplier power in the generics market in Italy, 2016
Figure 46: Factors influencing the likelihood of new entrants in the generics market in Italy, 2016
Figure 47: Factors influencing the threat of substitutes in the generics market in Italy, 2016
Figure 48: Drivers of degree of rivalry in the generics market in Italy, 2016
Figure 49: Japan generics market value: $ billion, 2012–16
Figure 50: Japan generics market volume: % of total pharma volume, 2012–16
Figure 51: Japan generics market geography segmentation: % share, by value, 2016
Figure 52: Japan generics market value forecast: $ billion, 2016–21
Figure 53: Japan generics market volume forecast: % of total pharma volume, 2016–21
Figure 54: Forces driving competition in the generics market in Japan, 2016
Figure 55: Drivers of buyer power in the generics market in Japan, 2016
Figure 56: Drivers of supplier power in the generics market in Japan, 2016
Figure 57: Factors influencing the likelihood of new entrants in the generics market in Japan, 2016
Figure 58: Factors influencing the threat of substitutes in the generics market in Japan, 2016
Figure 59: Drivers of degree of rivalry in the generics market in Japan, 2016
Figure 60: Russia generics market value: $ billion, 2012–16
Figure 61: Russia generics market volume: % of total pharma volume, 2012–16
Figure 62: Russia generics market geography segmentation: % share, by value, 2016
Figure 63: Russia generics market value forecast: $ billion, 2016–21
Figure 64: Russia generics market volume forecast: % of total pharma volume, 2016–21
Figure 65: Forces driving competition in the generics market in Russia, 2016
Figure 66: Drivers of buyer power in the generics market in Russia, 2016
Figure 67: Drivers of supplier power in the generics market in Russia, 2016
Figure 68: Factors influencing the likelihood of new entrants in the generics market in Russia, 2016
Figure 69: Factors influencing the threat of substitutes in the generics market in Russia, 2016
Figure 70: Drivers of degree of rivalry in the generics market in Russia, 2016
Figure 71: United Kingdom generics market value: $ billion, 2012–16
Figure 72: United Kingdom generics market volume: % of total pharma volume, 2012–16
Figure 73: United Kingdom generics market geography segmentation: % share, by value, 2016
Figure 74: United Kingdom generics market value forecast: $ billion, 2016–21
Figure 75: United Kingdom generics market volume forecast: % of total pharma volume, 2016–21
Figure 76: Forces driving competition in the generics market in the United Kingdom, 2016
Figure 77: Drivers of buyer power in the generics market in the United Kingdom, 2016
Figure 78: Drivers of supplier power in the generics market in the United Kingdom, 2016
Figure 79: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2016
Figure 80: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2016
Figure 81: Drivers of degree of rivalry in the generics market in the United Kingdom, 2016
Figure 82: United States generics market value: $ billion, 2012–16
Figure 83: United States generics market volume: % of total pharma volume, 2012–16
Figure 84: United States generics market geography segmentation: % share, by value, 2016
Figure 85: United States generics market value forecast: $ billion, 2016–21
Figure 86: United States generics market volume forecast: % of total pharma volume, 2016–21
Figure 87: Forces driving competition in the generics market in the United States, 2016
Figure 88: Drivers of buyer power in the generics market in the United States, 2016
Figure 89: Drivers of supplier power in the generics market in the United States, 2016
Figure 90: Factors influencing the likelihood of new entrants in the generics market in the United States, 2016
Figure 91: Factors influencing the threat of substitutes in the generics market in the United States, 2016
Figure 92: Drivers of degree of rivalry in the generics market in the United States, 2016
Figure 93: Mylan Inc.: revenues & profitability
Figure 94: Mylan Inc.: assets & liabilities
Figure 95: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 96: Teva Pharmaceutical Industries Limited: assets & liabilities
Figure 97: STADA Arzneimittel AG: revenues & profitability
Figure 98: STADA Arzneimittel AG: assets & liabilities
Figure 99: Sanofi SA: revenues & profitability
Figure 100: Sanofi SA: assets & liabilities
Figure 101: Daiichi Sankyo Co., Ltd.: revenues & profitability
Figure 102: Daiichi Sankyo Co., Ltd.: assets & liabilities
Figure 103: Sawai Pharmaceutical Co., Ltd.: revenues & profitability
Figure 104: Sawai Pharmaceutical Co., Ltd.: assets & liabilities
Figure 105: Abbott Laboratories: revenues & profitability
Figure 106: Abbott Laboratories: assets & liabilities
Figure 107: Krka, d. d., Novo mesto: revenues & profitability
Figure 108: Krka, d. d., Novo mesto: assets & liabilities

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report